India-based Cipla Ltd., a pharmaceutical company, has been awarded about US$189 million of the Global Fund Tender for anti-retroviral (ARV) drugs. Cipla was been selected as a ‘Panel Supplier’ under the Supplier Partnership Agreement. The contract is effective for 3 years starting this year. The supplies will begin from Q4 FY 2015.
Mr. Subhanu Saxena, MD & Global CEO, Cipla Limited said: “We are extremely proud to have won this tender from Global Fund. Cipla has been committed to the cause of HIV/AIDS for over two decades and this tender offers us a great opportunity to make HIV/AIDS treatment accessible to more than 140 countries through Global Fund.”
Created in 2002, the Global Fund operates as a partnership between governments, civil society, the private sector and people affected by the diseases. Focused on diseases such as AIDS, tuberculosis and malaria, the Global Fund raises and invests nearly US$4 billion a year to support programs run by local experts in more than 140 countries.
Programs supported by the Global Fund have put 7.3 million people on antiretroviral therapy for HIV, have tested and treated 12.3 million people for TB, and have distributed 450 million mosquito nets to protect families against malaria.
This article is based on materials provided by http://bit.ly/1wZC2mR